AuRx is currently seeking accredited investors!

Please contact Dr. Gary Calton at gcalton@aurx.com for more information.

AuRx is a biotech company developing a treatment for cancer with a modified herpes simplex type 2 virus, deltaPK. It destroys cancer cells without harming normal cells in both breast cancer and  melanoma while killing the cells that cause recurrence.

AuRx seeks funds to run clinical trials for ΔPK, an oncolytic herpes virus, for treatment of breast cancer.  We have patent coverage for the production of a recombinant HSV-2 (herpes virus), which had no serious side effects in a clinical trial in humans. ΔPK does not grow in normal human cells but rapidly grows in cancer cells, including cancer stem cells (15 days for a 0.5 cm lesion), destroying them. HSV-2 also destroy lung, colorectal, head and neck, pancreatic, renal, prostate, brain, ovarian and melanoma in cell studies .  ΔPK has not shown resistance development in multiple treatments in a triple negative breast cell model. ΔPK has shown cancer stem cells eradication whereas other HSV-2 in the literature have shown recurrence of tumors in animal models or incomplete eradication.

Over 267,000 women in the US will be diagnosed with invasive breast cancer this year in the US.  An additional 67,000 will be diagnosed with CIS, a stage 0 cancer. 47,000 women will die due to recurrence of their tumors, either locally or in other organs.  Treatment consists of surgery, radiation and chemotherapy, all of which have significant impacts on quality of life. Non-metastatic breast cancer normally consumes 1 year or more while metastatic breast cancer takes a minimum of more than 15 months of treatment with recovery times for each treatment phase consuming additional time.  The current average cost of chemotherapy is $18,000, however, new immunological treatments start at $70,000 and range far higher for combination therapy.

If clinical trials confirm the animal and cell models in being completely effective in less than 30 days, and eradicating recurrence due to cancer stem cells, ΔPK could be used in all cases of breast cancer.  Additional uses in lung, colorectal, head and neck, pancreatic, renal, prostate, brain, ovarian and melanoma cancers is also anticipated, each of which has markets ranging from 9,000 to 234,000 cases each year.